Working… Menu
Trial record 39 of 855 for:    LENALIDOMIDE AND Angiogenesis

Lenalidomide and Obinutuzumab for Previously Untreated CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02371590
Recruitment Status : Withdrawn (Study Not Activated Due to Contract Issues)
First Posted : February 25, 2015
Last Update Posted : February 23, 2018
Celgene Corporation
Genentech, Inc.
Information provided by (Responsible Party):
Michael Choi, University of California, San Diego

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2022